Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025GenesOpen Access

Toward Precision Medicine: Molecular Biomarkers of Response to Tofacitinib in Inflammatory Bowel Disease

View Full Paper
Ask AI
Bookmark
Share

Authors

ABAnja BizjakUniversity of MariborBGBoris GoleUniversität UlmGJGregor JezernikUniversity of Maribor

Discussion

Loading...

Member takes

Overview

This review identifies biomarkers predicting response to tofacitinib in inflammatory bowel disease, highlighting challenges in treatment efficacy.

Key Points

  • Up to 60% of ulcerative colitis patients showed inadequate response to tofacitinib, emphasizing variability.
  • The emergence of biomarkers such as CpG methylation signatures could assist in tailoring precision medicine strategies.
  • Tofacitinib operates as a JAK inhibitor, affecting inflammatory pathways and showing dose-dependent effectiveness.
  • The identification of predictors is crucial for optimizing patient outcomes in inflammatory bowel disease management.

Cite This Study

Bizjak et al. (2025) studied this question.

synapsesocial.com/papers/68c19fa854b1d3bfb60db620https://doi.org/10.3390/genes16080908
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Macrophage-Derived IGF-1 Is a Potent Coordinator of Myogenesis and Inflammation in Regenerating Muscle2015 · 54 citations
  2. 2Serum miRNA signature diagnoses and discriminates murine colitis subtypes and predicts ulcerative colitis in humans2017 · 45 citations
  3. 3Regenerative Wound Healing: The Role of Interleukin-102013 · 251 citations
  4. 4Activated type 17 helper T cells affect tofacitinib treatment outcomes2025 · 1 citations
  5. 5CircRNA_103765 acts as a proinflammatory factor via sponging miR-30 family in Crohn’s disease2021 · 37 citations